Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00259-022-06048-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
177 Lu-FAP-2286 Therapy in a Case of Squamous Lung Cancer.
Clin Nucl Med
January 2025
Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
We reported a 72-year-old man who was diagnosed with squamous lung cancer and received 2 cycles of 177 Lu-FAP-2286 treatment. Radiological remission was observed on follow-up FAP imaging 7 months later with squamous cell carcinoma antigen decreased to normal level. No other abnormality monitored by routine laboratory examination was noted.
View Article and Find Full Text PDFPreclinical Evaluation of Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors.
J Nucl Med
October 2024
R&D Department, Philochem AG, Otelfingen, Switzerland;
Article Synopsis
- Fibroblast activation protein (FAP) is commonly found in the stroma of human tumors, making it a target for cancer detection using radiolabeled ligands, such as the newly discovered OncoFAP, which shows rapid tumor accumulation and low healthy tissue uptake.
- A trimerized version called OncoFAP-23 has improved binding affinity and was tested in tumor-bearing mice, demonstrating a favorable biodistribution profile with significant tumor retention and minimal healthy tissue accumulation.
- Combining OncoFAP-23 with the interleukin 2 treatment shows increased anti-tumor effects and a strong immune response, while also displaying a good safety profile with no observed toxicity.
Evaluating the efficacy of [Lu]Lu-FAP-2286 in combination therapy for metastatic breast cancer.
Eur J Nucl Med Mol Imaging
November 2024
Department of Nuclear Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
177 Lu-FAP-2286 Therapy in a Patient With Metastatic Rhabdoid Meningioma.
Clin Nucl Med
September 2024
Rhabdoid meningioma is a rare subtype of meningioma and has a poor prognosis. Herein, we reported a patient of rhabdoid meningioma with multiple liver, pancreas, and bone metastases, who received 177 Lu-FAP-2286 therapy. After 1 treatment cycle, 68 Ga-FAP-2286 PET/CT revealed partial remission of the lesions.
View Article and Find Full Text PDFMetastatic Lung Adenocarcinoma Received Combined 177 Lu-FAP-2286 Radiation Therapy and Targeted Therapy.
Clin Nucl Med
June 2024
From the Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University; Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province; and Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China.
Article Synopsis
- - A 56-year-old man with advanced lung cancer (metastatic lung adenocarcinoma) underwent a new treatment combining radiation therapy (177 Lu-FAP-2286) and targeted therapy.
- - After just one cycle of treatment, he showed noticeable improvement in symptoms and achieved radiological remission, meaning the cancer appeared to shrink on imaging tests.
- - Importantly, the patient did not experience any negative side effects from the therapies, which is a positive outcome in cancer treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!